Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Cara Therapeutics (CARA)

Cara Therapeutics (CARA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Cara: Q4 Earnings Snapshot

Cara: Q4 Earnings Snapshot

CARA : 0.7900 (+1.52%)
Mira Pharmaceuticals Stock Is Soaring In November... Here's Why

Leveraging a favorable DEA classification for its synthetic analog of THC, Mira Pharmaceuticals could be on an expedited pathway toward commercialization to treat several unmet neurological m

MIRA : 0.7500 (+2.32%)
CARA : 0.7900 (+1.52%)
CRBP : 38.82 (+0.13%)
HRMY : 30.90 (-2.12%)
JAZZ : 109.85 (-0.15%)
Cara: Q3 Earnings Snapshot

Cara: Q3 Earnings Snapshot

CARA : 0.7900 (+1.52%)
Cara: Q2 Earnings Snapshot

Cara: Q2 Earnings Snapshot

CARA : 0.7900 (+1.52%)
Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

/CNW/ -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that England's National Institute for...

CARA : 0.7900 (+1.52%)
Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

/PRNewswire/ -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that England's National Institute...

CARA : 0.7900 (+1.52%)
Cara: Q1 Earnings Snapshot

Cara: Q1 Earnings Snapshot

CARA : 0.7900 (+1.52%)
Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates

Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 10% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

DARE : 0.3060 (-1.67%)
CARA : 0.7900 (+1.52%)
ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates

scPharmaceuticals, Inc. (SCPH) delivered earnings and revenue surprises of 16.67% and 20.65%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

SCPH : 4.73 (+1.50%)
CARA : 0.7900 (+1.52%)
Regenxbio (RGNX) Reports Q1 Loss, Misses Revenue Estimates

Regenxbio (RGNX) delivered earnings and revenue surprises of -0.66% and 37.92%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

RGNX : 16.87 (+0.24%)
CARA : 0.7900 (+1.52%)

Barchart Exclusives

After Its Historic Dividend Cut, Is 3M Stock Still Worth Buying?
3M stock is a Dividend King no more, as the company slashed its payout following the Solventum spinoff. Is the stock still a buy for investors seeking passive income? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar